Verve Therapeutics, Inc.
VERV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VERV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2025.
Tracking 4 pipeline candidates · 4 clinical trials for Verve Therapeutics, Inc..
Run Verve Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Verve Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
52.2 months
D/E 0.30
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is Verve Therapeutics, Inc.'s lead drug candidate?
Verve Therapeutics, Inc.'s most advanced tracked candidate is verve-101 (Phase 1) for Heterozygous Familial Hypercholesterolemia.
Who is the CEO of Verve Therapeutics, Inc.?
Sekar Kathiresan, M.D. is the chief executive officer of Verve Therapeutics, Inc. (VERV).
What therapeutic areas does Verve Therapeutics, Inc. focus on?
Verve Therapeutics, Inc. develops therapies across Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.